Journal
THERANOSTICS
Volume 4, Issue 1, Pages 47-80Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.7447
Keywords
positron emission tomography; Ga-68; radiochemistry; coordination chemistry; conjugation chemistry
Categories
Ask authors/readers for more resources
Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the Ga-68-radiopharmaceuticals must be put in the context of several aspects such as role of PET in nuclear medicine, unmet medical needs, identification of new biomarkers, targets and corresponding ligands, production and availability of Ga-68, automation of the radiopharmaceutical production, progress of positron emission tomography technologies and image analysis methodologies for improved quantitation accuracy, PET radiopharmaceutical regulations as well as advances in radiopharmaceutical chemistry. The review presents the prospects of the Ga-68-based radiopharmaceutical development on the basis of the current status of these aspects as well as wide range and variety of imaging agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available